拉米夫定对慢性乙型肝炎孕妇病毒动态的干预效果及安全性观察  

Observations on Virus Development Intervention Efficacy and Safely of Lamivudine in Treatment of Chronic Hepatitis B Patients with Pregnancy

作　　者：马静[1] 隋景玉[1] 白宝敏[1] 杨孜[1] 符丽华[1] 

机构地区：[1]中山市博爱医院,广东中山528403

出　　处：《中国实用医药》2006年第1期19-21,共3页China Practical Medicine

摘　　要：目的临床观察拉米夫定干预下慢性乙型肝炎孕妇的病毒动态及安全性。方法对拉米夫定治疗中发现早孕而继续服药的18例慢性乙型肝炎孕妇及发现早孕而停止服药的22例乙型肝炎孕妇,分别观察其病毒动态、妊娠并发症、婴幼儿HBV感染率及发育异常发生率。结果18例继续服用拉米夫定治疗的慢性乙型肝炎孕妇中16例HBV-DNA阴性,18例孕妇所产婴儿HBV感染率为零,妊娠并发症为零,尚未发现婴幼儿发育异常情况。而停止服药的22例慢性乙型肝炎孕妇中,19例HBV-DNA阳性。其婴儿HBV感染率41.9%,有17例发生妊娠并发症。结论拉米夫定可有效降低孕妇HBV-DNA水平,有助于阻断母婴传播,也有助于降低乙型肝炎妊娠并发症。Objective To investigate the influence on virus development intervention efficacy and safely of lamivudine in treatment of chronic hepatitis B patients with pregnancy.Methods 18 women with chronic hepatitis B were found in early pregnancy during lamivudine treatment, and 22 women stop lamivudine treatment. We observed the virus development, pregnancy complication, infants HBV virus infection rates,and fetal malformation.Results 16 women HBV-DNA turn negative of 18 women with chronic hepatitis B with treatment, while 19 women HBV-DNA positive of 22 women stop lamivudine treatment. Neither HBV virus infection rates, nor pregnancy complication and fetal malformation in lamivudine treatmentgroup, but there was 17 cases occurred pregnancy complication and 40.9% HBV virus infection rates in infant without lamivudine treatment group.Conclusion Lamivudine is beneficial in prevention mother to infant transmission and in reduction of complications and HBV-DNA level in patients of chronic hepatitis B with pregnancy.

关 键 词：拉米夫定 乙型肝炎病毒 孕妇 

分 类 号：R512.62[医药卫生—内科学]